PTK2 and B-cell chronic lymphocytic leukemia: We used defactinib, a selective inhibitor of FAK and PYK2 already used in clinical investigations for solid tumours and we exploited it in vitro and in vivo models, demonstrating an effect in all tested settings on CLL cells.